Steatocystoma Multiplex



First described by Jamieson[1] in 1873, and coined by Pringle in 1899, steatocystoma multiplex (SM) is an uncommon disorder of the pilosebaceous unit characterized by the development of numerous sebum-containing dermal cysts. Although steatocystoma multiplex has historically been described as an autosomal dominant inherited disorder, most presenting cases are sporadic.[2]

Steatocystoma simplex is the sporadic solitary tumor counterpart to steatocystoma multiplex.


Steatocystoma multiplex occurs as either a sporadic or autosomal dominant inherited condition characterized by benign sebaceous gland tumors. Lesions consist of a nevoid formation of abortive hair follicles at the site where sebaceous glands attach. Electron microscopy studies demonstrate cyst wall cells undergoing trichilemmal keratinization similar to that of the isthmus portion of the outer hair sheath. The relationship of steatocystoma multiplex to the development of sebaceous glands and common presentation at puberty suggest a hormonal trigger for lesion growth.

In the familial form of steatocystoma multiplex, mutations are localized to the keratin 17 (K17) gene in areas identical to mutations found in patients with pachyonychia congenita type 2 (PC-2). Pachyonychia congenita type 2, an autosomal dominant inherited disorder, is characterized by hypertrophic nail dystrophy, focal keratoderma, multiple pilosebaceous cysts, and a variety of conditions associated with ectodermal dysplasia. Keratin 17 is expressed in several epithelial structures, most notably in sebaceous glands, the outer root sheath of hair follicles, and the nail bed; its expression correlates well to the clinical phenotypic expression of both steatocystoma multiplex and pachyonychia congenita type 2. To date, 14 mutations have been described in patients with either steatocystoma multiplex or pachyonychia congenita type 2, all of which are localized to the helix initiation domain (1A domain) of the K17 gene.[3]

Some authors propose that steatocystoma multiplex is simply a variant of pachyonychia congenita type 2 because they both share the same underlying etiology. Sporadic forms of steatocystoma multiplex have not been shown to be associated with K17 mutations. In previous reports, specific mutations were attributed to early-onset cyst formation in pachyonychia congenita type 2 and steatocystoma multiplex; however, more recent reports suggest that the age of onset is multifactorial.[3]

Steatocystoma multiplex is associated with eruptive vellus hair cysts (EVHCs). Both diseases share overlapping clinical features, including age of onset, location, appearance of lesions, and mode of inheritance. Reports of hybrid lesions showing histological features of both steatocystoma multiplex and eruptive vellus hair cysts exist.[4, 5] Given these similarities, some postulate that steatocystoma multiplex and eruptive vellus hair cysts are, in fact, variants of the same disease.[2] However, major differences in keratin expression patterns between steatocystoma multiplex and eruptive vellus hair cysts have been elucidated, leading others to believe that they are 2 distinct disease entities.[6] In steatocystoma multiplex associated with eruptive vellus hair cyst, no K17 mutation has been found.



United States

Steatocystoma multiplex is considered rare; the true incidence is unknown.


Steatocystoma multiplex is a benign disorder. In some patients, it may have psychosocial implications resulting from the disfigurement due to widespread lesions or from scarring seen in the inflammatory variant, steatocystoma suppurativa.


No racial predilection has been found.


Both sexes are equally affected.


In the classic presentation, cysts manifest during adolescence and early adulthood, with average age of onset of 26 years.[2] Cases of steatocystoma multiplex presenting at birth have been reported,[7] and sporadic forms of steatocystoma multiplex with presentation as late as 78 years have been described.[8] Once present, steatocystoma multiplex is a lifelong condition.


Affected individuals often present with an increasing number of smooth flesh-to-yellow–colored cysts. The cysts are usually nontender and asymptomatic. On occasion, individual lesions may rupture into the dermis, become inflamed, and form sinus tracts with scarring. Secondary bacterial colonization can lead to malodorous discharge.


Lesions present as numerous flesh-to-yellow–colored dermal cysts ranging in size from 3 mm to 3 cm. Individual cysts range from elastic to firm and are often freely movable. The lesions lack a central punctum. Cyst contents appear as an odorless creamy or oily fluid. Individual lesions of steatocystoma multiplex may become suppurative, increase in size, and become prone to rupture (termed steatocystoma multiplex suppurativum). In these cases, secondary bacterial colonization often leads to malodorous discharge. Significant scarring with sinus tract formation may occur.

In typical cases of steatocystoma multiplex, cysts are distributed in areas where high numbers of sebaceous glands are found, most commonly the chest, arms, axillae, and neck. Several reports of localized steatocystoma multiplex limited to the scalp, face, retroauricular region, groin, and nasal region have been reported.[9, 10] Acral steatocystoma multiplex, in which involvement of the extremities is more prominent than the trunk, is uncommon and was described by Rollins et al in 2000.[11]

View Image

Steatocystoma multiplex on the chest of an adolescent female.

View Image

Steatocystoma multiplex with typical-appearing, smooth, yellow and white dermal cysts.

While some authors refer to localized steatocystoma multiplex as a specific condition, it shares pathological and clinical features of typical cases and is thought to represent a variant of the steatocystoma multiplex rather than a separate disease entity.[9] Linear variants have been reported,[7] and, although rare, generalized eruptions may occur.


Steatocystoma multiplex is a disorder of the pilosebaceous unit that occurs in either a sporadic or an autosomal dominant fashion. Androgenic stimulation of the sebaceous gland, along with environmental factors and the site and type of the keratin mutation, influence the onset of the sebaceous cysts.[3]

Histologic Findings

Cysts are located in the mid dermis. The cyst lining is a crenulated or wavy, homogeneous, eosinophilic horny layer collapsed around thin cystic spaces. The spaces hold varying amounts of keratin, vellus hairs, and sebum esters, the latter of which often are removed by tissue processing. Walls are formed from several layers of epithelial cells, with embedded flattened lobules of sebaceous glands among the epithelial cells. Invaginations resembling hair follicles can also be found emptying into the cyst. Cyst units may be attached to the overlying normal epidermis by a thin strand of undifferentiated epithelial cells. All reported cases of steatocystoma multiplex exhibit an eosinophilic cuticle and lack of a granular layer. In contrast, eruptive vellus hair cysts are lined by mature squamous cells with a granular layer and are not associated with sebaceous glands.

View Image

Note the crenulated eosinophilic lining of the cyst wall (10X magnification).

View Image

Note the sebaceous glands within the cyst wall (2X scanning view).

Medical Care

Medical treatments have been used with variable results to lessen inflammation, minimize scarring, and reduce the need for surgery.

Surgical Care

Cysts can be widespread and difficult to treat. A variety of surgical treatment options have been used in the treatment of steatocystoma multiplex.

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.


Clinical Context:  Treats gram-positive and gram-negative organisms and mycoplasmal, chlamydial, and rickettsial infections. Inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunit(s). Also useful for its anti-inflammatory effects.

Class Summary

Tetracycline derivatives with their anti-inflammatory side effects have been helpful in treating steatocystoma suppurativa.

Isotretinoin (Amnesteem, Claravis, Myorisan, Sotret)

Clinical Context:  Synthetic 13-cis isomer of naturally occurring tretinoin (trans -retinoic acid). Both agents are related structurally to beta-carotene. Decreases sebaceous gland size and sebum production. May inhibit sebaceous gland differentiation and abnormal keratinization.

Only those physicians experienced or trained in use should prescribe. A US Food and Drug Administration–mandated registry is now in place for all individuals prescribing, dispensing, or taking isotretinoin. For more information on this registry, see iPLEDGE. This registry aims to further decrease the risk of pregnancy and other unwanted and potentially dangerous adverse effects during a course of isotretinoin therapy.

Class Summary

Decrease size of sebaceous glands and decrease their sebum production. Retinoids also have anti-inflammatory effects by decreasing production of certain leukotrienes.


The prognosis for patients with steatocystoma multiplex is excellent. No reports describe malignant transformation within these benign adnexal tumors.


Mathew A Davey, MD, FAAD, Dermatologist, Advanced Dermatology of the Midlands; Omaha, Nebraska

Disclosure: Nothing to disclose.


Craig N Burkhart, MD, MSBS, Assistant Professor, Department of Dermatology, University of North Carolina at Chapel Hill School of Medicine

Disclosure: Nothing to disclose.

Dean Scott Morrell, MD, Professor, Director of Dermatology Residency Training Program, Director of Pediatric and Adolescent Dermatology, Department of Dermatology, University of North Carolina at Chapel Hill

Disclosure: Nothing to disclose.

Specialty Editors

Arash Taheri, MD, Research Fellow, Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Steven R Feldman, MD, PhD, Professor, Departments of Dermatology, Pathology and Public Health Sciences, Wake Forest University Health Sciences; Director, Center for Dermatology Research, Director, Psoriasis Treatment Center, Director of Industry Relations, Department of Dermatology, Wake Forest University School of Medicine

Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Galderma Honoraria Speaking and teaching; Taro Consulting fee Consulting; Ownership interest Management position; Causa Reseasrch Ownership interest Management position; Janssen Consulting; Pfizer Honoraria Speaking and teaching; Novartis Consulting fee Consulting; Celgene Consulting fee Consulting

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania

Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, Mary Bane, MD, to the development and writing of this article.


  1. Jamieson WA. Case of numerous cutaneous cysts scattered over the body. Edin Med J. 1873;19:223-5.
  2. Cho S, Chang SE, Choi JH, Sung KJ, Moon KC, Koh JK. Clinical and histologic features of 64 cases of steatocystoma multiplex. J Dermatol. Mar 2002;29(3):152-6. [View Abstract]
  3. Oh SW, Kim MY, Lee JS, Kim SC. Keratin 17 mutation in pachyonychia congenita type 2 patient with early onset steatocystoma multiplex and Hutchinson-like tooth deformity. J Dermatol. Mar 2006;33(3):161-4. [View Abstract]
  4. Yamada A, Saga K, Jimbow K. Acquired multiple pilosebaceous cysts on the face having the histopathological features of steatocystoma multiplex and eruptive vellus hair cysts. Int J Dermatol. Oct 2005;44(10):861-3. [View Abstract]
  5. Papakonstantinou E, Franke I, Gollnick H. Facial steatocystoma multiplex combined with eruptive vellus hair cysts: a hybrid?. J Eur Acad Dermatol Venereol. Jul 30 2014;[View Abstract]
  6. Tomková H, Fujimoto W, Arata J. Expression of keratins (K10 and K17) in steatocystoma multiplex, eruptive vellus hair cysts, and epidermoid and trichilemmal cysts. Am J Dermatopathol. Jun 1997;19(3):250-3. [View Abstract]
  7. Park YM, Cho SH, Kang H. Congenital linear steatocystoma multiplex of the nose. Pediatr Dermatol. Mar-Apr 2000;17(2):136-8. [View Abstract]
  8. Riedel C, Brinkmeier T, Kutzne H, Plewig G, Frosch PJ. Late onset of a facial variant of steatocystoma multiplex - calretinin as a specific marker of the follicular companion cell layer. J Dtsch Dermatol Ges. Jun 2008;6(6):480-2. [View Abstract]
  9. Mortazavi H, Taheri A, Mansoori P, Kani ZA. Localized forms of steatocystoma multiplex: Case report and review of the literature. Dermatology Online Journal [serial online]. 2005;11:22. Available from: Accessed October 21, 2008. Available at
  10. Lee D, Chun JS, Hong SK, Seo JK, Choi JH, Koh JK, et al. Steatocystoma multiplex confined to the scalp with concurrent alopecia. Ann Dermatol. Oct 2011;23:S258-60. [View Abstract]
  11. Rollins T, Levin RM, Heymann WR. Acral steatocystoma multiplex. J Am Acad Dermatol. Aug 2000;43(2 Pt 2):396-9. [View Abstract]
  12. Duzova AN, Senturk GB. Suggestion for the treatment of steatocystoma multiplex located exclusively on the face. Int J Dermatol. Jan 2004;43(1):60-2. [View Abstract]
  13. Schmook T, Burg G, Hafner J. Surgical pearl: mini-incisions for the extraction of steatocystoma multiplex. J Am Acad Dermatol. Jun 2001;44(6):1041-2. [View Abstract]
  14. Kaya TI, Ikizoglu G, Kokturk A, Tursen U. A simple surgical technique for the treatment of steatocystoma multiplex. Int J Dermatol. Dec 2001;40(12):785-8. [View Abstract]
  15. Lee SJ, Choe YS, Park BC, Lee WJ, Kim do W. The vein hook successfully used for eradication of steatocystoma multiplex. Dermatologic Surgery. 2008;33:82-84.
  16. Choudhary S, Koley S, Salodkar A. A modified surgical technique for steatocystoma multiplex. J Cutan Aesthet Surg. Jan 2010;3(1):25-8. [View Abstract]
  17. Rossi R, Cappugi P, Battini M, Mavilia L, Campolmi P. CO2 laser therapy in a case of steatocystoma multiplex with prominent nodules on the face and neck. Int J Dermatol. Apr 2003;42(4):302-4. [View Abstract]
  18. Krahenbuhl A, Eichmann A, Pfaltz M. CO2 laser therapy for steatocystoma multiplex. Dermatologica. 1991;183(4):294-6. [View Abstract]
  19. Bakkour W, Madan V. Carbon dioxide laser perforation and extirpation of steatocystoma multiplex. Dermatol Surg. Jun 2014;40(6):658-62. [View Abstract]
  20. Laquer VT, Wu JJ, Tournas JA, Murase JE, Dyson SW. Pruritic bluish-black subcutaneous papules on the chest. Dermatol Online J. Mar 15 2008;14(3):14. [View Abstract]

Steatocystoma multiplex on the chest of an adolescent female.

Steatocystoma multiplex with typical-appearing, smooth, yellow and white dermal cysts.

Note the crenulated eosinophilic lining of the cyst wall (10X magnification).

Note the sebaceous glands within the cyst wall (2X scanning view).

Steatocystoma multiplex on the chest of an adolescent female.

Steatocystoma multiplex with typical-appearing, smooth, yellow and white dermal cysts.

Note the crenulated eosinophilic lining of the cyst wall (10X magnification).

Note the sebaceous glands within the cyst wall (2X scanning view).